Cell Technologies in the Stress Urinary Incontinence Correction
Igor Maiborodin,
Gennadiy Yarin,
Sergey Marchukov,
Aleksandra Pichigina,
Galina Lapii,
Sergey Krasil’nikov,
Svetlana Senchukova,
Maxim Ryaguzov,
Inna Vilgelmi,
Maksim Bakarev,
Vitalina Maiborodina
Affiliations
Igor Maiborodin
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Gennadiy Yarin
The Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia
Sergey Marchukov
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Aleksandra Pichigina
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Galina Lapii
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Sergey Krasil’nikov
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Svetlana Senchukova
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Maxim Ryaguzov
The Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia
Inna Vilgelmi
The Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, akademika Lavrenteva str., 8, 630090 Novosibirsk, Russia
Maksim Bakarev
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
Vitalina Maiborodina
Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine” of the Ministry of Science and Higher Education of the Russian Federation, Timakova st., 2, 630117 Novosibirsk, Russia
The scientific literature of recent years contains a lot of data about using multipotent stromal cells (MSCs) for urinary incontinence correction. Despite this, the ideal treatment method for urinary incontinence has not yet been created. The cell therapy results in patients and experimental animals with incontinence have shown promising results, but the procedures require further optimization, and more research is needed to focus on the clinical phase. The MSC use appears to be a feasible, safe, and effective method of treatment for patients with urinary incontinence. However, the best mode for application of cell technology is still under study. Most clinical investigations have been performed on only a few patients and during rather short follow-up periods, which, together with an incomplete knowledge of the mechanisms of MSC action, does not make it possible for their widespread implementation. The technical details regarding the MSC application remain to be identified in more rigorous preclinical and clinical trials.
